NFSG
VVOS icon

Newbridge Financial Services Group’s Vivos Therapeutics VVOS Stock Holding History

Newbridge Financial Services Group’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,275
Closed -$2.83K – 1104
2024
Q2 		$2.83K Sell
1,275
-675
-35% -$1.65K ﹤0.01% 918
2024
Q1 		$9.42K Buy
1,950
+655
+51% +$3.91K ﹤0.01% 780
2023
Q4 		$16.1K Buy
+1,295
New +$11.1K 0.01% 632

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Newbridge Financial Services Group's VVOS Position: Q3 2024 in Review

Newbridge Financial Services Group sold out of Vivos Therapeutics (VVOS) in Q3 2024, closing a stake of 1,275 shares — an estimated $2.83K sold.

Newbridge Financial Services Group first reported a position in VVOS in Q4 2023 and held it in 3 quarters. The position peaked at $16.1K in Q4 2023. 23 funds tracked by Wall St. Rank hold VVOS as of Q3 2024.

  • Newbridge Financial Services Group reported no remaining Vivos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Newbridge Financial Services Group sold 1,275 Vivos Therapeutics shares in Q3 2024, an estimated $2.83K.
  • Newbridge Financial Services Group first reported a position in Vivos Therapeutics in Q4 2023 and held it in 3 quarters.
  • Newbridge Financial Services Group's Vivos Therapeutics position peaked at $16.1K in Q4 2023.
  • 23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2024.

Based on Newbridge Financial Services Group's 13F filing for Q3 2024, filed 12 Nov 2024.